Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | ALB | P02768 | 4/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20567326 | 0.92 | GLP1R (0.45) | GLP1RFOLH1ALB | |
| SCHEMBL20567323 | 0.92 | GLP1R (0.45) | GLP1RFOLH1ALB | |
| SCHEMBL28400630 | 0.92 | GLP1R (0.50) | GLP1RFOLH1NOD1GLO1 | |
| SCHEMBL28400628 | 0.92 | GLP1R (0.50) | GLP1RFOLH1NOD1GLO1 | |
| SCHEMBL20567466 | 0.92 | GLP1R (0.50) | GLP1RFOLH1NOD1GLO1 | |
| SCHEMBL20567468 | 0.92 | GLP1R (0.50) | GLP1RFOLH1NOD1GLO1 | |
| SCHEMBL24179868 | 0.92 | GLP1R (0.50) | GLP1RFOLH1ALBNOD1 | |
| SCHEMBL19270361 | 0.92 | GLP1R (0.50) | GLP1RFOLH1ALBNOD1GLO1 | |
| SCHEMBL14550481 | 0.89 | GLP1R (0.53) | GLP1RFOLH1ALBNOD1 | |
| SCHEMBL15871504 | 0.89 | GLP1R (0.54) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079722-B1 | METHOD FOR THIOETHER CONJUGATION OF PROTEINS | NOVO NORDISK HEALTHCARE AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| US-20190203213-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-04 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160303248-A1 | Method for Thioether Conjugation of Proteins | NOVO NORDISK HEALTH CARE AG (CH) | 2016-10-20 | — | — | US | disclosed |
| WO-2015086853-A1 | METHOD FOR THIOETHER CONJUGATION OF PROTEINS | NOVO NORDISK HEALTH CARE AG (DK) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303248-A1 | Method for Thioether Conjugation of Proteins | TST, P4HB, PDIA6 | GLP1R 4417/4885FOLH1 205/4885ALB 77/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | GLP1R 101/4885FOLH1 469/4885ALB 15/4885 |
| US-20190203213-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | GLP1R 101/4885FOLH1 469/4885ALB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.